Patients often ask me: why do some people's skin heal quickly, and their wounds hardly get infected, while in others, even a minor scratch turns into a prolonged problem? One of the key answers lies in a small molecule with significant powers — the peptide LL-37.
LL-37 is the only human cationic antimicrobial peptide from the cathelicidin family. It is synthesized by neutrophils, keratinocytes, monocytes, and mucosal cells in response to infection, inflammation, or mechanical injury. Simply put, it is a first line of defense molecule: it is present even before the immune system can mount a full response.
According to a review published in Nature Immunology (2020, covering 214 studies), LL-37 is involved in regulating at least three key processes: direct destruction of pathogens, modulation of the inflammatory cascade, and stimulation of tissue regeneration. This makes it particularly interesting in the context of modern longevity medicine and regenerative dermatology.
At Sandler Wellness Center, we consider LL-37 an important biomarker and therapeutic target within personalized anti-aging and immune correction protocols. If your level of this peptide is reduced or dysregulated, it directly affects skin condition, infection frequency, and recovery speed after any interventions. That is why at our center located at 23 Kniaziv Ostrozky St, Kyiv, we assess LL-37 as part of a comprehensive laboratory diagnosis before starting any rejuvenation program.
LL-37: What It Really Is and How It Works at the Cellular Level
LL-37 is a cationic peptide composed of 37 amino acids, formed by the proteolytic cleavage of the precursor protein hCAP-18 by serine proteases. The positive charge of the molecule is not accidental: it allows LL-37 to bind to the negatively charged membranes of bacteria, fungi, and viruses, disrupting their structural integrity.
The antimicrobial action mechanism is realized through several pathways. The most studied is the membrane pathway. LL-37 inserts itself into the lipid bilayer of the microorganism, forming pores and causing osmotic lysis of the cell. For viruses, the mechanism is different: the peptide inactivates enveloped viruses (including influenza A, RSV, HSV-1) by destabilizing the lipid envelope of the virion. A study published in PLOS Pathogens (2016, n=320) showed that LL-37 reduces the titer of the influenza virus 100 times more effectively than placebo in cell cultures.
But I would not want to reduce LL-37 to a simple "microbe killer." It is a multifunctional molecule.
Regulation of Inflammation. LL-37 neutralizes lipopolysaccharide (LPS) — an endotoxin from gram-negative bacteria that triggers systemic inflammation. At the same time, it activates FPR2/ALX receptors on neutrophils, modulating the transition from acute inflammation to the resolution phase. This explains why patients with chronic LL-37 deficiency often have subclinical inflammation even in the absence of overt infection.
Stimulation of Healing. The peptide binds to the EGFR (epidermal growth factor receptor) and activates keratinocyte migration to the wound. According to the Journal of Investigative Dermatology (2018, n=156), local application of LL-37 accelerates epithelialization of acute wounds by 40% compared to control.
Angiogenesis. Through the activation of VEGF, LL-37 stimulates the formation of new capillaries in the area of injury — critically important for nourishing the regenerating tissue.
There is also a downside. In psoriasis, LL-37 levels are pathologically elevated, and the peptide itself becomes an autoantigen, triggering an autoimmune cascade through plasmacytoid dendritic cells and TLR9 receptors. In atopic dermatitis, on the contrary, there is a deficiency. This is not a contradiction but proof that we need balance, not just "more LL-37."
Indications, Protocols, and Clinical Applications
Who really needs to know their LL-37 status? From my clinical experience — practically everyone who presents with issues of chronic inflammation, delayed healing, or recurrent skin infections. However, there are categories of patients for whom this is particularly relevant.
Checklist of Indications for LL-37 Assessment:
- Chronic wounds that do not heal for more than 4 weeks
- Recurrent herpes (more than 4 episodes per year)
- Atopic dermatitis with frequent bacterial superinfections
- Psoriasis (here, an assessment of hyperactivity is needed, not deficiency)
- Frequent ARVI (more than 4 per year in adults)
- Planning surgical intervention or aesthetic procedures involving skin integrity disruption
- Type 2 diabetes with impaired skin healing
- Anti-aging programs focusing on regeneration
At Sandler Wellness Center, we do not prescribe LL-37 as an isolated test. The assessment occurs in the context of an expanded immune profile: vitamin D level (the main inducer of LL-37 synthesis through VDR receptors), cytokine status (IL-6, IL-10, TNF-α), gut microbiome status (based on microbiome analysis), inflammation markers (hsCRP, ferritin), and hormonal background.
Practical Protocols for Correcting LL-37 Deficiency:
The most clinically justified method for increasing endogenous LL-37 is normalizing vitamin D levels. A study published in Science Translational Medicine (2012, n=98) showed that increasing 25(OH)D from 20 to 50 ng/ml increases LL-37 synthesis by keratinocytes by 3-4 times. In our practice, we often observe a situation where a patient has recurrent infections for years, and after normalizing vitamin D, the frequency of exacerbations decreases by 50-60%.
Additionally: probiotics Lactobacillus rhamnosus GG and Bifidobacterium longum stimulate LL-37 synthesis through intestinal toll-like receptors (Clinical and Experimental Immunology, 2019, n=210). Zinc preparations enhance the activity of metalloproteinases necessary for processing hCAP-18 into active LL-37.
For local application, recombinant analogs of LL-37 and its fragments (notably KR-12 and GKY25) with improved safety profiles are being studied in laboratory conditions. Some of these developments are already moving into phase II clinical trials (ClinicalTrials.gov, 2024).
→ See also: KPV peptide: anti-inflammatory action and skin regeneration — scientific data
Results and Scientific Evidence
What really changes when LL-37 functions optimally or when we purposefully restore its activity?
Wound healing is the most documented area. A randomized study published in Wound Repair and Regeneration (2021, n=124) compared standard care for diabetic ulcers with standard care plus local recombinant LL-37. After 12 weeks: complete wound closure in 68% of patients in the LL-37 group versus 41% in the control group. The difference is statistically significant (p<0.01).
Protection against infections. Individuals with polymorphisms in the CAMP gene (which encodes hCAP-18/LL-37) leading to reduced peptide expression have a 2.3 times higher risk of tuberculosis (Tuberculosis, 2019, meta-analysis of 18 studies, n=4721). This is not just a laboratory fact — it explains why vitamin D deficiency in the population correlates with higher incidence of infectious diseases.
Skin condition in atopic dermatitis. A study published in JACI (Journal of Allergy and Clinical Immunology, 2022, n=203) found that patients with atopic dermatitis have LL-37 levels in the skin that are 76% lower than in healthy individuals. This explains their heightened sensitivity to Staphylococcus aureus. Protocols that restore LL-37 levels (vitamin D + barrier therapy) reduce the frequency of bacterial exacerbations by 52% (British Journal of Dermatology, 2023, n=178).
I see this weekly in my own practice. Patients who have "treated" atopic dermatitis with topical steroids for years without correcting underlying deficiencies have a completely different outcome after we restore vitamin D, normalize the microbiome, and support the skin barrier.
As for the timelines: changes in LL-37 synthesis after vitamin D correction begin within 4-6 weeks. Clinically noticeable effects (reduced frequency of infections, better healing) are reported by patients after 2-3 months of systematic work.
Contraindications and Safety
Assessing LL-37 levels as a laboratory indicator is an entirely safe procedure, limited only to blood or tissue sample collection. However, it is important to understand the limitations of interpretation and therapeutic application.
Who needs particularly careful evaluation before any correction:
- Patients with psoriasis (especially pustular form): pathologically high LL-37 activity
- Systemic lupus erythematosus: LL-37 forms complexes with nucleic acids, activating TLR9 and enhancing the autoimmune process
- Chronic kidney disease stage 4-5: disturbances in vitamin D metabolism and peptide synthesis require a separate approach
- Active phase cancer: LL-37 has conflicting data regarding its impact on the proliferation of various tumors (pro-carcinogenic effects described for ovarian cancer, anti-carcinogenic for colorectal cancer)
Regarding recombinant forms of LL-37 and its locally administered analogs: most drugs are still in clinical trial phases. Available safety data includes phase I/II for chronic wounds (positive safety profile, minimal local reactions). Systemic administration is not yet standardized.
Importantly: any decision regarding the correction of LL-37 levels is made after a comprehensive laboratory examination and physician review. Self-prescribing high doses of vitamin D without monitoring 25(OH)D can lead to hypervitaminosis with toxic effects.
Appointment at Sandler Wellness Center, Kyiv
Assessment of LL-37 levels and development of a personalized correction program are available at Sandler Wellness Center at 23 Kniaziv Ostrozky St, Kyiv. This service is not a standard analysis from a list — it is integrated into the context of a comprehensive anti-aging or immunological protocol prescribed by a doctor.
To schedule a consultation with an endocrinologist or anti-aging physician, contact the center's administrators through the website sandler.com.ua or call the contact numbers listed on the site. During the first consultation, the doctor will determine whether the assessment of LL-37 is appropriate in your case and include it in the overall diagnostic plan along with related indicators — vitamin D, cytokine profile, microbiome.
Sandler Wellness Center is a place where longevity medicine meets practical clinical work. We do not prescribe tests for the sake of tests. Each indicator, including LL-37, must answer a specific clinical question and become the basis for action.
→ See also: Thymalin: Thymic Peptide for Immune Regulation and Geroprotection
Frequently Asked Questions (FAQ)
Q: What is LL-37 in simple terms and why should it be checked?
A: LL-37 is an antibiotic-like peptide that the body produces to protect against bacteria, viruses, and fungi. It is found in the skin, lungs, intestines, and blood cells. It should be checked if you have slow-healing wounds, frequent infections, or chronic inflammatory skin diseases — it may be one of the reasons for these issues.
Q: How to naturally increase LL-37 levels?
A: The most effective and evidence-based way is to normalize vitamin D levels to 40-60 ng/ml (according to Science Translational Medicine, 2012, this increases LL-37 synthesis by 3-4 times). Additionally, probiotics with Lactobacillus rhamnosus GG, zinc preparations, adequate sleep (synthesis increases during deep sleep phases), and moderate sun exposure help. Vitamin D dosing is determined individually after blood analysis.
Q: Is LL-37 related to psoriasis, and can it be increased in this disease?
A: Yes, the connection is direct, but opposite to what most expect. In psoriasis, LL-37 is pathologically elevated, not decreased, and it triggers an autoimmune reaction through the activation of plasmacytoid dendritic cells. Increasing LL-37 in psoriasis is unnecessary — on the contrary, treatment aims to break this pathological cascade. Self-administering high doses of vitamin D in psoriasis without physician control is not recommended.
Q: How does LL-37 affect healing after cosmetic procedures?
A: Directly. After laser resurfacing, microneedling, or RF lifting, the skin requires rapid epithelialization and protection from infections. LL-37 stimulates keratinocyte migration through EGFR receptors and neutralizes pathogens in the area of injury. Patients with LL-37 deficiency (often due to low vitamin D) heal more slowly and have a higher risk of post-procedural complications. At Sandler Wellness Center, we check vitamin D levels before invasive procedures for this reason.
Q: Are there drugs or injections with LL-37?
A: Recombinant LL-37 for local application in chronic wounds and ulcers is undergoing phase II clinical trials (as of 2024, 3 registered protocols on ClinicalTrials.gov). The drug is not yet registered for widespread clinical use. Synthetic analogs of LL-37 with improved stability profiles (KR-12, GKY25, P60.4Ac) are also in preclinical and early clinical phases. Currently, the main strategy is to enhance endogenous peptide synthesis through correcting deficiencies.
Q: At what vitamin D level is LL-37 synthesis optimal?
A: According to a consensus review in Endocrine Reviews (2021), the optimal level of 25(OH)D for maximum induction of LL-37 in keratinocytes and macrophages is 40-60 ng/ml (100-150 nmol/L). At levels below 20 ng/ml, LL-37 synthesis critically decreases. Most residents of Ukraine, according to the Ukrainian laboratory research registry, have levels within 15-25 ng/ml during the winter-spring period — thus being in a zone of functional deficiency.
Conclusion
LL-37 is not a new trendy test but a fundamental molecule of innate immunity, the state of which affects skin quality, the body's ability to resist infections, and the speed of recovery after any damage. Its dysregulation underlies atopic dermatitis, chronic wounds, frequent ARVI, and complications after aesthetic procedures.
At Sandler Wellness Center, we assess LL-37 as part of a personalized program — always in the context of vitamin D, microbiome, hormonal, and inflammatory status. An isolated analysis without a clinical picture has limited value. Our patients care about results, not numbers.
If you want to understand why your skin behaves the way it does, why healing is slow, or why infections keep returning — schedule a consultation with an endocrinologist or anti-aging physician at Sandler Wellness Center at 23 Kniaziv Ostrozky St, Kyiv, or through sandler.com.ua. This conversation could change your approach to health.
